{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T10:49:34Z","timestamp":1792406974000,"version":"4.4.0"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,1]]},"abstract":"<jats:sec>\n                    <jats:title>Aims:<\/jats:title>\n                    <jats:p>To evaluate the results of chemoradiation with intensity-modulated radiation therapy (IMRT) or volumetric-modulated arc therapy (VMAT) for the treatment of anal canal cancer patients at three institutions that had advanced devices.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>A retrospective analysis was performed for patients treated with 5-fluorouracil and mitomycin-based chemotherapy and IMRT or VMAT for anal cancer from 2011 to 2013. Complete response (CR) rates, colostomy-free survival (CFS), disease-free survival (DFS), overall survival (OS), and toxicities were investigated. Toxicities were evaluated with the Common Terminology Criteria for Adverse Events, Version 3.0.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Fifteen patients were included in the analysis. The majority of patients had T2 (53.3%) and N0 (40%) disease according to the staging system that was developed by the American Joint Committee on Cancer. CR was observed in 14 patients (93%), and the median follow-up was 26 months (13\u201342 months). The 3-year CFS, DFS, and OS were 86%, 86%, and 88%, respectively. Acute Grade 3 toxicities were observed as 6% of hematological, 26% of gastrointestinal, and 26% of dermatological.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Early results confirm that IMRT or VMAT for anal cancer treatment reduces acute toxicities while maintaining high control rates.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jcrt.jcrt_774_16","type":"journal-article","created":{"date-parts":[[2020,1,30]],"date-time":"2020-01-30T03:49:15Z","timestamp":1580356155000},"page":"51-55","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":7,"title":["Outcomes of patients with anal cancer treated with volumetric-modulated arc therapy or intensity-modulated radiotherapy and concurrent chemotherapy"],"prefix":"10.4103","volume":"17","author":[{"given":"Serap","family":"Yucel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huseyin","family":"Kadioglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeynep","family":"Gural","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuleyha","family":"Akgun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esra Kaytan","family":"Saglam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-9-20241021","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1007\/BF02586980","article-title":"Combined therapy for cancer of the anal canal: A preliminary report","volume":"17","author":"Nigro","year":"1974","journal-title":"Dis Colon Rectum"},{"key":"R2-9-20241021","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1200\/JCO.1997.15.5.2040","article-title":"Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: Results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups","volume":"15","author":"Bartelink","year":"1997","journal-title":"J Clin Oncol"},{"key":"R4-9-20241021","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1200\/JCO.1996.14.9.2527","article-title":"Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: Results of a phase III randomized intergroup study","volume":"14","author":"Flam","year":"1996","journal-title":"J Clin Oncol"},{"key":"R5-9-20241021","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1001\/jama.299.16.1914","article-title":"Fluorouracil, mitomycin, and radiotherapy vs. fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: A randomized controlled trial","volume":"299","author":"Ajani","year":"2008","journal-title":"JAMA"},{"key":"R6-9-20241021","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ijrobp.2012.09.023","article-title":"RTOG 0529: A phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal","volume":"86","author":"Kachnic","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R7-9-20241021","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ijrobp.2010.09.030","article-title":"Dose-painted intensity-modulated radiation therapy for anal cancer: A multi-institutional report of acute toxicity and response to therapy","volume":"82","author":"Kachnic","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R8-9-20241021","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/0360-3016(91)90265-6","article-title":"Epidermoid anal cancer: Treatment by radiation alone or by radiation and 5-fluorouracil with and without mitomycin C","volume":"21","author":"Cummings","year":"1991","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R9-9-20241021","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1007\/BF02049397","article-title":"Respective roles of radiotherapy and surgery in the management of epidermoid carcinoma of the anal margin. Series of 57 patients","volume":"35","author":"Papillon","year":"1992","journal-title":"Dis Colon Rectum"},{"key":"R10-9-20241021","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/0167-8140(93)90076-K","article-title":"Chemoradiation therapy for anal cancer: Radiation plus continuous infusion of 5-fluorouracil with or without cisplatin","volume":"27","author":"Rich","year":"1993","journal-title":"Radiother Oncol"},{"key":"R11-9-20241021","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1634\/theoncologist.12-5-524","article-title":"Anal cancer: An overview","volume":"12","author":"Uronis","year":"2007","journal-title":"Oncologist"},{"key":"R12-9-20241021","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/sj.bjc.6605605","article-title":"Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR anal cancer trial (ACT I)","volume":"102","author":"Northover","year":"2010","journal-title":"Br J Cancer"},{"key":"R13-9-20241021","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S1470-2045(13)70086-X","article-title":"Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): A randomised, phase 3, open-label, 2 \u00d7 2 factorial trial","volume":"14","author":"James","year":"2013","journal-title":"Lancet Oncol"},{"key":"R14-9-20241021","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1200\/JCO.2011.35.4837","article-title":"Induction chemotherapy and dose intensification of the radiation boost in locally advanced anal canal carcinoma: Final analysis of the randomized UNICANCER ACCORD 03 trial","volume":"30","author":"Peiffert","year":"2012","journal-title":"J Clin Oncol"},{"key":"R15-9-20241021","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1200\/JCO.2008.19.6857","article-title":"US intergroup anal carcinoma trial: Tumor diameter predicts for colostomy","volume":"27","author":"Ajani","year":"2009","journal-title":"J Clin Oncol"},{"key":"R16-9-20241021","doi-asserted-by":"crossref","first-page":"4007","DOI":"10.1002\/cncr.25188","article-title":"Prognostic factors derived from a prospective database dictate clinical biology of anal cancer: The intergroup trial (RTOG 98-11)","volume":"116","author":"Ajani","year":"2010","journal-title":"Cancer"},{"key":"R17-9-20241021","doi-asserted-by":"crossref","first-page":"4344","DOI":"10.1200\/JCO.2012.43.8085","article-title":"Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: Survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil\/mitomycin versus fluorouracil\/cisplatin","volume":"30","author":"Gunderson","year":"2012","journal-title":"J Clin Oncol"},{"key":"R18-9-20241021","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/jso.21866","article-title":"Is neoadjuvant chemotherapy prior to radio-chemotherapy beneficial in T4 anal carcinoma?","volume":"104","author":"Moureau-Zabotto","year":"2011","journal-title":"J Surg Oncol"},{"key":"R19-9-20241021","first-page":"205","article-title":"Dose escalation in chemoradiation for anal cancer: Preliminary results of RTOG 92-08","volume":"2","author":"John","year":"1996","journal-title":"Cancer J Sci Am"},{"key":"R20-9-20241021","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s10350-007-9125-z","article-title":"Squamous-cell carcinoma of the anal canal: Predictors of treatment outcome","volume":"51","author":"Roohipour","year":"2008","journal-title":"Dis Colon Rectum"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.JCRT_774_16","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:37:17Z","timestamp":1787067437000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.JCRT_774_16"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.4103\/jcrt.jcrt_774_16","relation":{},"ISSN":["0973-1482"],"issn-type":[{"value":"0973-1482","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]}}}